LoadingLoadingLoadingNet selling: insiders sold $33.1M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full results8 funds hold a position and insiders have been net selling.
Sells/Trims (2)
Citadel
$163.6M
sold
Marshall Wace
$52.8M
trimmed
Sells (3)
Patel Dinesh V Ph D
$18.2M
sold
Patel Dinesh V Ph D
$14.9M
sold
Waddill William D.
$1.1M
sold
Top-trader positions in PTGX could not be loaded.
Hyperliquid positioning - not every stock is covered
Last report
Aug 5, 2026
Period ending
Jun 30, 2026
Earnings per share
$2.11 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 24, 2026
EPS expected
$0.13 to $3.40
Revenue expected
12 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 5, 2026 | $2.29 / $2.11Alpha Vantage | +8.53% beat | $213.5M No estimate | Unavailable |
| Mar 31, 2026 | May 5, 2026 | $0.05 / -$0.65Alpha Vantage | +107.69% beat | $56.4M No estimate | Unavailable |
| Dec 31, 2025 | Feb 25, 2026 | -$0.69 / -$0.34Alpha Vantage | -102.76% miss | $7.4M No estimate | Unavailable |
| Sep 30, 2025 | Nov 6, 2025 | -$0.62 / -$0.64Alpha Vantage | +3.13% beat | $4.7M No estimate | Unavailable |
| Jun 30, 2025 | Aug 6, 2025 | -$0.55 / -$0.52Alpha Vantage | -5.77% miss | $5.5M No estimate | Unavailable |
| Mar 31, 2025 | May 6, 2025 | -$0.19 / $0.11Alpha Vantage | -$0.30 miss | $28.3M No estimate | Unavailable |
| Dec 31, 2024 | Feb 21, 2025 | $1.98 / $0.25Alpha Vantage | +$1.73 beat | $170.6M No estimate | Unavailable |
| Sep 30, 2024 | Nov 7, 2024 | -$0.54 / -$0.53Alpha Vantage | -1.89% miss | $4.7M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $4.7M | $7.4M | $56.4M | $213.5M |
| Cost of what it sold | — | $376.0K | $407.0K | — |
| Gross profit | $4.7M | $7.4M | $56.0M | $213.5M |
| What it spent | ||||
| Research and development | $40.0M | $46.4M | $46.7M | $42.1M |
| Sales and admin | $11.1M | $11.4M | $13.3M | $12.6M |
| Total operating expenses | $51.1M | $57.8M | $59.6M | $54.7M |
| What was left | ||||
| Operating profit | -$46.4M | -$50.4M | -$3.6M | $158.8M |
| Profit before tax | -$39.3M | -$43.7M | $2.3M | $165.1M |
| Tax | — | $666.0K | -$1.5M | $2.3M |
| Net profit | -$39.3M | -$44.4M | $3.8M | $162.8M |
| EBITDA | -$39.0M | -$43.3M | $2.7M | $165.5M |
This stock is in a strong uptrend.
Trend
Strong uptrend
80 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
TD Cowen maintains Buy rating on Protagonist Therapeutics, $160 price target
BullishOct 21A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
BullishOct 20Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
BullishOct 19Protagonist Therapeutics, Inc. (PTGX) Stock forecasts
Leans bearishOct 18Form 4 Protagonist Therapeutics Inc: Asif Ali (CFO) For: 30 September By Investing.com
NeutralOct 18Form 4 Protagonist Therapeutics Inc: Asif Ali (CFO) For: 30 September
NeutralOct 18Form 4 Protagonist Therapeutics Inc: Asif Ali (CFO) For: 30 September
NeutralOct 17Protagonist Therapeutics (NASDAQ:PTGX) Raised to Strong-Buy at Zacks Research
BullishOct 16